Trulieve becomes first major US cannabis operator to list on NYSE

Trulieve Cannabis Corp. started trading on the New York Stock Exchange on June 10, making it the first US-based, plant-touching cannabis company to land on a major American exchange. The stock, trading under the ticker TRLV, opened between $10 and $12 per share, giving the company a market capitalization of roughly $2 billion.

How Trulieve got to the big board

Cannabis companies have historically been barred from major US exchanges because marijuana was classified as a Schedule I substance under federal law. That meant even profitable, multi-state operators were stuck on over-the-counter markets or Canadian exchanges. Trulieve previously traded under the tickers TRUL and TCNNF.

The Trump administration’s reclassification of medical marijuana to Schedule III changed the calculus. DEA-registered medical marijuana operations could now, in theory, trade on major US exchanges. But companies still needed to separate themselves from adult-use, recreational cannabis to comply with the new regulatory framework.

Trulieve’s solution was a corporate spin-off. The company carved out its adult-use cannabis operations into a new entity called Harvest Enterprises. External investors acquired a 10% stake in Harvest, creating a clean separation between the medical operations that could list on the NYSE and the recreational business that still carries more regulatory baggage.

CEO Kim Rivers has positioned the listing as a way to unlock shareholder access and boost the company’s visibility with institutional investors who previously couldn’t, or wouldn’t, touch cannabis stocks.

What this means for the cannabis sector and investors

Many pension funds, mutual funds, and ETFs have mandates that restrict them to securities listed on major exchanges. A cannabis company trading on the Canadian Securities Exchange simply doesn’t show up on their radar, no matter how strong the fundamentals. Trulieve just made itself eligible for inclusion in a universe of capital that was previously off-limits.

By spinning off its adult-use operations into Harvest Enterprises, the company voluntarily shed exposure to the recreational cannabis market, which in many states is the faster-growing segment. Investors in TRLV are now betting on a medical-only business, which carries different growth characteristics and margin profiles than a vertically integrated operator spanning both categories.

The Harvest Enterprises spin-off itself is worth watching. That 10% external investor stake suggests the recreational entity may eventually seek its own public listing or additional fundraising rounds.